{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:37:06Z","timestamp":1791247026282,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myosin inhibitors investigated in symptomatic hypertrophic cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">Using a systematic search, 10 clinical trials with safety and efficacy data for either drug in obstructive hypertrophic cardiomyopathy (oHCM) and nonobstructive hypertrophic cardiomyopathy were included. Additionally, we included data from regulatory agencies. Both drugs demonstrated substantial benefit in reducing left ventricular outflow tract obstruction (Valsalva left ventricular outflow tract gradients improved by \u221245\u2009mm\u2009Hg or better), symptom burden (placebo\u2010corrected New York Heart Association class improvement \u22651 of at least 30%), and cardiac biomarkers (geometric mean ratio of 0.2 for N\u2010terminal pro\u2010B\u2010type natriuretic peptide) while improving exercise parameters (improved placebo\u2010corrected peak oxygen consumption of at least 1.4 to 1.8\u2009mL\/kg\u2009per\u2009minute) in patients with oHCM. Both drugs were generally well\u2010tolerated, although patients on mavacamten had higher rates of treatment interruption (partly protocol\u2010driven, 8.7% versus 0.5%, respectively, in oHCM) due to left ventricular ejection fraction reduction, atrial fibrillation (11.5 versus 4.1 per 100 patient\u2010years, respectively, in oHCM), and heart failure (1.7 versus 0.0 per 100 patient\u2010years, respectively, in oHCM) compared with aficamten. These comparisons are limited by a shorter exposure duration to aficamten, and longer follow\u2010up is needed. The data in nonobstructive hypertrophic cardiomyopathy are derived from phase II trials, with phase III trials ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Mavacamten and aficamten represent effective medications for the treatment of symptomatic oHCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.124.038758","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:43:51Z","timestamp":1741391031000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy"],"prefix":"10.1161","author":[{"given":"Bryton J.","family":"Davis","sequence":"first","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Volk","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6801-0744","authenticated-orcid":false,"given":"Olives","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3680-7329","authenticated-orcid":false,"given":"Daniel","family":"Kamna","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-9251","authenticated-orcid":false,"given":"Hongya","family":"Chen","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3487","authenticated-orcid":false,"given":"Roberto","family":"Barriales\u2010Villa","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV Coru\u00f1a Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia\u2010Pavia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro de Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Meyer Children\u2019s Hospital IRCCS Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine of the University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3208-470X","authenticated-orcid":false,"given":"Caroline J.","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Glasgow Glascow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Abraham","sequence":"additional","affiliation":[{"name":"University of California San Francisco San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Brigham and Women\u2019s Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-3853","authenticated-orcid":false,"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[{"name":"Tufts University and Lahey Hospital &amp; Medical Center Burlington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021332"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.06"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43197"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae198"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2024.01.022"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3456"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-024-00505-0"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","unstructured":"Owens A Sherrid M Rader F Wong T Wever\u2010Pinzon O Choudhury L Fox S Shah A Balaratnam G Masri A. Cumulative long\u2010term efficacy and safety of mavacamten treatment in nonobstructive hypertrophic cardiomyopathy: updated interim analysis from the MAVERICK cohort of the MAVA\u2010long\u2010term extension (LTE) study up to 120\u2009weeks. In: Oral Presentation at: Hypertrophic Cardiomyopathy Society 2023. Cleveland; 2023. doi: 10.1016\/j.cardfail.2023.11.004.","DOI":"10.1016\/j.cardfail.2023.11.004"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.1844"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.09.028"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae579"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.020"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.07.003"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.02.020"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)02346-5"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3372"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401424"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035993"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856"},{"key":"e_1_3_1_29_2","unstructured":"European Medicines Agency . Camzyos: European Public Assessment Report (EPAR)\u2014Product Information. 2023."},{"key":"e_1_3_1_30_2","unstructured":"United States Food and Drug Administration Center for Drug Evaluation and Research . Clinical and Statistical Review(s): Mavacamten (Camzyos). 2022."},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01290"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.04.008"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167295"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.10.004"},{"key":"e_1_3_1_35_2","unstructured":"Maron M. Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA\u2010HCM an international multicenter phase 3 trial. In: Oral Presentation at: European Society of Cardiology Heart Failure 2024. Lisbon; 2024."},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.02.006"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2737"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.27.701"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad518"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi1001344"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00274.2002"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3005"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014240"},{"key":"e_1_3_1_47_2","volume-title":"Camzyos U.S. Prescribing Information","author":"Bristol\u2010Myers Squibb Company","year":"2023","unstructured":"Bristol\u2010Myers Squibb Company . Camzyos U.S. Prescribing Information. Princeton: Bristol\u2010Myers Squibb Company; 2023."},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2041"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062534"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.097997"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.09.1381"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2021.11.2179"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad429"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.124.038758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T23:43:56Z","timestamp":1741391036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.124.038758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":53,"alternative-id":["10.1161\/JAHA.124.038758"],"URL":"https:\/\/doi.org\/10.1161\/jaha.124.038758","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e038758"}}